Investors concerned over Synergy's health
Provider of sterilisation services, Synergy Health, saw both revenue and profit rise for the six months ended 2 October, but shares fell lower on Thursday after the firm gave an uncertain outlook on the healthcare market.
Provider of sterilisation services, Synergy Health, saw both revenue and profit rise for the six months ended 2 October, but shares fell lower on Thursday after the firm gave an uncertain outlook on the healthcare market.
Like-for-like revenue rose 11.9% from £138.7m to £155.3m, while pre-tax profit was £16.6m, up 11.1% from the same period last year. Meanwhile, net debt grew from £117.5m to £149.2m, while operating cash flow dipped slightly from £38.4m to £36.1m.
However, Synergy did warn that the current economic climate in the UK and Europe has created "increased cost awareness", having an impact on publicly funded healthcare markets: "This more challenging economic environment will ultimately have a positive impact on the rate of outsourcing, but whilst we have a period of uncertainty, customer decision making can be slow."
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Nevertheless, chief executive Richard Steeves remained confident that the group can achieve its full-year targets.
"We continue to make good progress with our strategy of developing Synergy's international presence in outsourced sterilisation services to hospitals and medical device manufacturers," he said. "The relatively resilient nature of the healthcare sector, our strong market position and barriers to entry, position us well to maintain growth."
The board will pay an interim dividend of 6.82p per share, up 13.7% on the same period last year (2010: 6p).
The share price fell 1.16% to 810.5p by 08:39.
NR
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Revolut finally bags a UK banking licence – what next for the fintech?
Revolut has finally been granted a UK banking licence following three years of negotiations with the regulator
By Kalpana Fitzpatrick Published
-
Could Labour impose a “double death tax” of more than 50%?
Speculation is mounting that capital gains tax will be reformed in the Budget - and one option is to charge bereaved families the tax on top of inheritance tax. We explain how it could work
By Ruth Emery Published